טוען...
(18)F-labeled anti-human CD20 cys-diabody for same-day immunoPET in a model of aggressive B-cell lymphoma in human CD20 transgenic mice
PURPOSE: Metabolic imaging using [(18)F]FDG is the current standard for clinical PET; however, some malignancies (e.g., indolent lymphomas) show low avidity for FDG. The majority of B-cell lymphomas express CD20, making it a valuable target both for antibody-based therapy and imaging. We previously...
שמור ב:
| הוצא לאור ב: | Eur J Nucl Med Mol Imaging |
|---|---|
| Main Authors: | , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6580847/ https://ncbi.nlm.nih.gov/pubmed/30456475 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-018-4214-x |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|